HeartBeam, Samsung Ink Strategic Alliance Deal

HeartBeam has begun a strategic alliance with Samsung, extending the existing agreement between LIVMOR and Samsung. HeartBeam acquired LIVMOR’s assets earlier this year.
 
Under the terms of the agreement, HeartBeam and Samsung will identify and define collaboration opportunities, leveraging the HeartBeam team’s expertise and technology to assess and monitor cardiac symptoms.
 
“The goal of this partnership is to bring standard of care for cardiac diagnostic capabilities to patients by utilizing cutting edge technologies of both Samsung and HeartBeam,” Branislav Vajdic, Ph.D., HeartBeam CEO and founder, told the press. “Our newly acquired state of the art, FDA cleared, Samsung watch-based arrhythmia detection tool, once integrated with the HeartBeam AIMIGo telehealth platform, presents a unique opportunity to extend our product capabilities well beyond what is currently available for cardiac patients outside of a medical setting.”
 
Kevin Jones, senior director, Federal Healthcare, Samsung Electronics America, added, “The strategic collaboration between Samsung and LIVMOR was very successful, resulting in an FDA cleared solution for Atrial Fibrillation detection centered around the Samsung Galaxy watch and tablet running Samsung’s defense-grade cyber-security system, Knox. We are excited that LIVMOR is now part of HeartBeam and look forward to continuing our successful collaboration. The potential of combining LIVMOR’s technology and the HeartBeam AIMIGo system holds significant promise to address major cardiac conditions for our veterans.”
 
LIVMOR developed the Halo atrial fibrillation (AF) detection system, an FDA-cleared prescription wearable for continuous monitoring of pulse rhythms to spot AF on-demand during the day, and automatically overnight. Under the previous strategic agreement, LIVMOR and Samsung built a physician-prescribed, fully integrated care platform that offers extended cardiovascular health monitoring in virtually any setting, using medical-grade equipment.
 
“Thanks to our cooperation with LIVMOR and Samsung, we are able to treat some of the nation’s most at-risk patients as safely and effectively from the comfort of their homes as we would if they were sitting in an exam room,” said Dr. Jerrold Grodin, Department of Veterans Affairs, North Texas. “We’ve seen an increase in early adoption from patients when their physicians are also early adopters.”
 
Among available opportunities is a possible collaboration with the Department of Veterans Affairs through its Accelerating VA Innovation and Learning (AVAIL) program. In September, the VA announced 17 companies won spots in a potential five-year, $650 million health tech research and development program. Participants provide subject-matter expertise to help the agency design, build, and test novel platforms, services, and care models that could be scaled into clinical production to support the Veterans Health Administration.